Overview

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Status:
Active, not recruiting

Trial end date:
2022-06-15

Target enrollment:

Participant gender:

Summary

This is an open-label, multi-center, multi-national, non-randomized rollover study designed to allow continued access to napabucasin for patients who have participated in a Boston Biomedical-sponsored study and are being treated with napabucasin (monotherapy or combination) and who are deriving continued clinical benefit in the parent study at the time of closure.

Phase:

Phase 1

Details

Lead Sponsor:

Boston Biomedical, Inc
Sumitomo Dainippon Pharma Oncology, Inc

Treatments:

Albumin-Bound Paclitaxel
Bevacizumab
Fluorouracil
Gemcitabine
Irinotecan
Leucovorin
Nivolumab
Paclitaxel